Treatment of Pancreatic Cancer Redding CA

Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say. Pancreatic cancer is resistant to every currently available anti-cancer treatment.

Ziad Asad Niazi, MD
(530) 244-9332
1760 Gold St
Redding, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Baghdad, Coll Of Med, Baghdad, Iraq
Graduation Year: 1962

Data Provided by:
Ziad A Niazi
(530) 244-9332
1760 Gold St
Redding, CA
Specialty
Urology

Data Provided by:
Paul Trygve Stratte
(530) 241-3316
2624 Edith Ave
Redding, CA
Specialty
Urology

Data Provided by:
Susan D Goldberg, MD
(530) 243-3803
2888 Eureka Way Ste 201
Redding, CA
Specialties
Urology
Gender
Female
Education
Medical School: Univ Of Toronto, Fac Of Med, Toronto, Ont, Canada
Graduation Year: 1978

Data Provided by:
Patrick Thos Fowler, MD
(530) 241-3316
2624 Edith Ave
Redding, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Ca, San Diego, Sch Of Med, La Jolla Ca 92093
Graduation Year: 1992

Data Provided by:
Patrick T Fowler
(530) 241-3316
2624 Edith Ave
Redding, CA
Specialty
Urology

Data Provided by:
Paul Trygve Stratte, MD
(530) 241-3316
2624 Edith Ave
Redding, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Ca, Irvine, Ca Coll Of Med, Irvine Ca 92717
Graduation Year: 1987
Hospital
Hospital: Mercy Med Ctr -Redding, Redding, Ca
Group Practice: Redding Urologic Associates

Data Provided by:
Anthony Mathias Thijssen, MD FACS
(530) 244-6001
2121 Airpark Dr
Redding, CA
Gender
Male
Education
Medical School: Ottawa
Graduation Year: 1985

Data Provided by:
Gregory Michael Lomas, MD
(530) 241-3316
2624 Edith Ave
Redding, CA
Specialties
Urology
Gender
Male
Education
Medical School: Mi State Univ Coll Of Human Med, East Lansing Mi 48824
Graduation Year: 1986

Data Provided by:
Maurer Robert E. MD
(530) 244-6001
2121 Airpark Dr
Redding, CA

Data Provided by:
Data Provided by:

Treatment of Pancreatic Cancer

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.

SOURCE: European Cancer Organization, news release, Sept. 24, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com